Navigation Links
Medication may prevent depression in patients with head and neck cancer

Taking the antidepressant citalopram before beginning treatment for head and neck cancer may help prevent depression during therapy, according to results of a pilot study published in the May issue of Archives of OtolaryngologyHead & Neck Surgery, one of the JAMA/Archives journals.

Treatment for head and neck cancer can be arduous and debilitating, the authors write as background information in the article. Psychiatric morbidity in these patients is frequent and underdiagnosed. Major depressive disorder has been reported in up to 40 percent of patients with head and neck cancer, typically within the first three months of diagnosis.

William M. Lydiatt, M.D., of the University of Nebraska Medical Center and Nebraska Methodist Hospital, Omaha, and colleagues conducted a randomized clinical trial involving patients with head and neck cancer. Before beginning treatment, 15 participants were randomly assigned to receive 40 milligrams of the antidepressant citalopram daily and 13 were randomly assigned to take placebo. The patients took the medications for 12 weeks, during which time they underwent cancer treatment and were screened for depression every four weeks. Twenty-two patients were assessed at week 12, and 23 patients completed a final study visit four weeks after stopping the medication.

The numbers of subjects who met predefined cutoff criteria for depression during the 12 weeks of active study were five of 10 (50 percent) taking placebo and two of 12 (17 percent) taking citalopram, the authors write. No patients in the citalopram group became suicidal, compared with two in the placebo group. Quality of life, as measured by a self-administered questionnaire, deteriorated in both groups during treatment but less so in the group taking citalopram.

The data from this pilot trial suggest that prevention of major depressive disorder in patients undergoing treatment for head and neck cancer may be an attainable goal. The data show trends toward major depressive disorder prevention in this small sample. All measures of psychiatric well-being favored the group taking citalopram, the authors conclude. This study suggests a tangible means to improve outcome in patients with head and neck cancer and supports additional research toward this aim.


Contact: Vicky Cerino
JAMA and Archives Journals

Related medicine news :

1. American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD
2. Migraine Medications May Cause Serotonin Syndrome
3. Chronic Medication Nation: Research Finds Chronic Health Problems Now Afflict More Than Half of All Americans
4. Nations First of its Kind Consumer Medication Return Initiative Creates Momentum for Safe Drug Disposal in the U.S.
5. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
6. Self-Medication One of Many Factors Driving OTC Drug Market Past $80 Billion by 2012
7. Quarter of Disabled Seniors Use Risky Medications
8. CNS Response, Inc.: Poster Session on Referenced-EEG Guided Medication to Be Presented at the American Psychiatric Association 161st Annual Meeting
9. Common Medications Could Cause Physical Impairment in the Elderly
10. Commonly used medications associated with impaired physical function in older adults
11. 1 in 10 children using cough, cold medications
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as ... Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. ...
(Date:11/30/2015)... ... ... Trevor and Taylor Crabb have unveiled an exciting new campaign to unite ... States. This hybrid crowdfunding campaign is designed to provide the Crabb brothers’ ... offering corporate sponsors with some great marketing deliverables with the brothers for the 2016 ...
(Date:11/30/2015)... ... ... The National Association of Professional Women (NAPW) honors Dawn ... She is recognized with this prestigious distinction for leadership in estate sales and moving. ... 850,000 members and over 200 operating Local Chapters. , “I’m pleased to welcome Dawn ...
(Date:11/30/2015)... ... December 01, 2015 , ... ... to offer individual vision insurance plans on . The multi-carrier insurance ... rate and review products, allowing consumers to compare, quote and match plans to ...
(Date:11/30/2015)... ... November 30, 2015 , ... During the National ... caregivers and held two webinars on topics of ‘Medical and Palliative Care Decisions,’ ... at . , With a loved one's diagnosis of mesothelioma, the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)...  QT Vascular Ltd., together with its subsidiaries (the ... TriReme Medical LLC and Quattro Vascular Pte. Ltd., collectively ... assembly and distribution of advanced therapeutic solutions for the ... announce that a three-judge panel of the ... Federal Circuit ("Federal Circuit") has unanimously granted the Group ...
(Date:11/30/2015)... ) has ... Market 2015-2019" report to their offering. ... of the "Orphan Drugs Market 2015-2019" ... and Markets ( ) has announced the ... report to their offering. ...
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
Breaking Medicine Technology: